{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:56:26Z","timestamp":1785527786689,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor\u2013positive, HER2-negative (HR+\/HER2\u2212) metastatic breast cancer is the most common type of advanced breast cancer. The addition of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors to endocrine therapy (ET) has made a marked change to patient outcomes. While clinical trials have established their efficacy, real-world studies like this one are needed to confirm their effectiveness given the many variables which may arise in patient demographics and clinical presentation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted on patients with HR+\/HER2\u2009\u2212\u2009metastatic breast cancer treated with palbociclib, ribociclib, or abemaciclib plus ET at Electricity Hospital, Cairo, Egypt, between January 2019 and January 2025. Data on demographics, clinical characteristics, and treatment outcomes were collected from medical records. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan\u2013Meier method, and prognostic variables were analyzed using Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 59 patients (94.9% female; median age 58 years) were included. De novo metastatic disease was present in 39%, and visceral metastases in 33.9%. Ribociclib was prescribed to 52.5%, palbociclib to 39%, and abemaciclib to 8.5%. The objective response rate (ORR) was 88.1%, and the clinical benefit rate (CBR) was 98.3%. Median PFS was 23.7 months (95% CI, 11.9\u201323.9), and median OS was 38.9 months (95% CI, 27.0\u201360.3). On univariate analysis, absence of brain metastases, endocrine sensitivity, treatment response, and neutropenia were linked to longer PFS and OS. Dose reduction did not negatively impact outcomes. Toxicities were generally manageable, with grade 3\u20134 neutropenia in 33.9% of patients and no febrile episodes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, CDK4\/6 inhibitors plus ET achieved survival outcomes similar to those reported in clinical trials, with a favorable safety profile. Endocrine sensitivity, absence of brain metastases, and development of neutropenia were associated with better survival, supporting the use of CDK4\/6 inhibitors across a broad patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00390-7","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:31:25Z","timestamp":1785252685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of CDK4\/6 inhibitors plus endocrine therapy in HR+\/HER2\u2009\u2212\u2009metastatic breast cancer: a single-institution experience"],"prefix":"10.1186","volume":"38","author":[{"given":"Nawal E.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"AbdAllah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha S.","family":"El Baghdady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"390_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","volume":"23","author":"J Ettl","year":"2021","unstructured":"Ettl J, Mueller V, Schmidt M, et al. Real-world efficacy and safety of CDK4\/6 inhibitors in HR+\/HER2\u2009\u2013\u2009metastatic breast cancer: Results from the PRAEGNANT registry. Breast Cancer Res. 2021;23(1):37.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"390_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"M Giuliano","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor\u2013positive, HER2\u2013negative metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360\u20139.","journal-title":"Lancet Oncol"},{"issue":"20","key":"390_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"20","key":"390_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"390_CR5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(21)00058-9","volume":"22","author":"M Cristofanilli","year":"2021","unstructured":"Cristofanilli M, Rugo HS, Im SA, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+\/HER2\u2009\u2013\u2009Advanced Breast Cancer: Updated Analysis of PALOMA-3. Lancet Oncol. 2021;22(4):419\u201329.","journal-title":"Lancet Oncol"},{"issue":"18","key":"390_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738\u201348.","journal-title":"N Engl J Med"},{"issue":"25","key":"390_CR7","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2\u2009\u2013\u2009Advanced Breast Cancer. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"17","key":"390_CR8","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1: Abemaciclib as a single agent in patients with refractory HR+\/HER2\u2009\u2013\u2009metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218\u201324.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"390_CR9","first-page":"e1234","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al. Management of neutropenia in patients receiving CDK4\/6 inhibitors. Oncologist. 2021;26(7):e1234\u201340.","journal-title":"Oncologist"},{"issue":"11","key":"390_CR10","first-page":"1005","volume":"37","author":"RS Mehta","year":"2019","unstructured":"Mehta RS, Barlow WE, Albain KS, et al. Overall Survival with Fulvestrant plus Anastrozole vs. Anastrozole Alone in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol. 2019;37(11):1005\u201312.","journal-title":"J Clin Oncol"},{"key":"390_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"390_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tbcr-25-37","volume":"7","author":"B Liu","year":"2026","unstructured":"Liu B, Wu T, Lu K, et al. Real-world efficacy and prognostic factors of CDK4\/6 inhibitors in HR+\/HER2- metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China. Transl Breast Cancer Res. 2026;7:2.","journal-title":"Transl Breast Cancer Res"},{"key":"390_CR13","first-page":"127","volume":"188","author":"A DeMichele","year":"2021","unstructured":"DeMichele A, et al. Real-world experience with palbociclib plus endocrine therapy in women with metastatic breast cancer. Breast Cancer Res Treat. 2021;188:127\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"390_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10549-020-05988-6","volume":"185","author":"SA Wander","year":"2021","unstructured":"Wander SA, et al. Clinical outcomes with palbociclib in metastatic breast cancer: real-world evidence. Breast Cancer Res Treat. 2021;185:709\u201318.","journal-title":"Breast Cancer Res Treat"},{"key":"390_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514\u201324. (MONALEESA-3).","journal-title":"N Engl J Med"},{"key":"390_CR16","first-page":"222","volume":"70","author":"F Schettini","year":"2020","unstructured":"Schettini F, et al. CDK4\/6 inhibitors in advanced breast cancer: A systematic review and meta-analysis of randomized trials. CA Cancer J Clin. 2020;70:222\u201338.","journal-title":"CA Cancer J Clin"},{"key":"390_CR17","doi-asserted-by":"publisher","first-page":"104568","DOI":"10.1016\/j.breast.2025.104568","volume":"83","author":"O Badran","year":"2025","unstructured":"Badran O, Darawshe A, Sharif S, Yosef S, Bar-Sela G. Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+\/HER-2 breast cancer patients treated with CDK4\/6 inhibitors. Breast. 2025;83:104568.","journal-title":"Breast"},{"key":"390_CR18","first-page":"130","volume":"59","author":"M Mart\u00edn","year":"2021","unstructured":"Mart\u00edn M, Johnston SRD, Huober J, et al. Safety and efficacy of dose reduction of ribociclib in patients with HR+\/HER2\u2009\u2013\u2009advanced breast cancer: Results from MONALEESA-2, -3, and \u2013\u20097 trials. Breast. 2021;59:130\u20137.","journal-title":"Breast"},{"issue":"9","key":"390_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/ijc.35296","volume":"156","author":"M Thill","year":"2025","unstructured":"Thill M, Zahn MO, Welt A, et al. Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry. Int J Cancer. 2025;156(9):1770\u201382.","journal-title":"Int J Cancer"},{"issue":"3","key":"390_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","volume":"21","author":"LM Spring","year":"2019","unstructured":"Spring LM, et al. CDK 4\/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.","journal-title":"Curr Oncol Rep"},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"103069","DOI":"10.1016\/j.ctrv.2025.103069","volume":"142","author":"YY Hoo","year":"2026","unstructured":"Hoo YY, Sia WW, Jaya-Prakason S, et al. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4\/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis. Cancer Treat Rev. 2026;142:103069.","journal-title":"Cancer Treat Rev"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00390-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00390-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00390-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:14:47Z","timestamp":1785521687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00390-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00390-7","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Research Ethics Committee, Faculty of Pharmacy, The British University in Egypt (Approval No. CL-2401). Permission to conduct the study and review patients\u2019 medical records was also obtained from Electricity Hospital, Cairo, Egypt. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"52"}}